Therapeutic antibody developer Patrys names new CEO
By Brie CarterTherapeutic antibody developer Patrys (ASX:PAB) appointed Dr. Samantha South as its new CEO, effective Feb. 16.
South joins the company with a distinguished track record in biotechnology, specializing in transitioning preclinical assets to clinical stages and navigating complex regulatory landscapes.
A founding director of Argenica Therapeutics and the current chair of the Life Sciences WA board, South brings a wealth of commercialisation experience from senior roles at leading Australian research institutions and various biotech spin-outs.
The appointment comes at a pivotal moment for Patrys as it evolves into a dual-platform, clinical-stage company.
South’s background—which includes a PhD, an MBA, and extensive research experience at institutions such as Cornell University and the Garvan Institute—is seen by the board as the ideal catalyst for accelerating value across the company’s expanding portfolio.
Patrys Chair Peter Christie emphasised that her unique combination of "scientific depth and commercial acumen" will be instrumental in guiding the company through its next phase of development and capital-efficient drug growth.
At the time of reporting, Patrys' share price was $0.036.
More from Australia
Arika Resources begins 3,000-metre drilling at Pennyweight Point
Core Energy Minerals starts 2,650m uranium drilling in Namibia
COSOL signs $11M US transit contract
ASIC plans to loosen pre-IPO advertising rules
Auric Mining secures $17M capital placement
Talga Group battery anode reaches 8,000 test cycles
